Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.

Viale, G; de Snoo, F A; Slaets, L; Bogaerts, J; van 't Veer, L; Rutgers, E J; Piccart-Gebhart, M J; Stork-Sloots, L; Glas, A; Russo, L; Dell'Orto, P; Tryfonidis, K; Litière, S; Cardoso, F

Viale, G; de Snoo, F A; Slaets, L; Bogaerts, J; van 't Veer, L; Rutgers, E J; Piccart-Gebhart, M J; Stork-Sloots, L; Glas, A; Russo, L; Dell'Orto, P; Tryfonidis, K; Litière, S; Cardoso, F.

Afiliación

Viale G; Department of Pathology, European Institute of Oncology and University of Milan, Via Ripamonti 435, 20141, Milan, Italy. giuseppe.viale@ieo.it.
de Snoo FA; Medical Affairs, Agendia, Amsterdam, The Netherlands.
Slaets L; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Bogaerts J; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
van 't Veer L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Rutgers EJ; Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Piccart-Gebhart MJ; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Stork-Sloots L; Medical Affairs, Agendia, Amsterdam, The Netherlands.
Glas A; Medical Affairs, Agendia, Amsterdam, The Netherlands.
Russo L; Department of Pathology, European Institute of Oncology and University of Milan, Via Ripamonti 435, 20141, Milan, Italy.
Dell'Orto P; Department of Pathology, European Institute of Oncology and University of Milan, Via Ripamonti 435, 20141, Milan, Italy.
Tryfonidis K; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Litière S; European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

Breast Cancer Res Treat ; 167(1): 123-131, 2018 01.

Article en En | MEDLINE | ID: mdl-28929359

Asunto(s)

Biomarcadores de Tumor/genética; Neoplasias de la Mama/tratamiento farmacológico; Proteínas de Neoplasias/genética; Pronóstico; Adulto; Anciano; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Neoplasias de la Mama/epidemiología; Neoplasias de la Mama/genética; Neoplasias de la Mama/patología; Supervivencia sin Enfermedad; Femenino; Perfilación de la Expresión Génica; Regulación Neoplásica de la Expresión Génica; Humanos; Hibridación Fluorescente in Situ; Antígeno Ki-67/genética; Persona de Mediana Edad; Terapia Neoadyuvante; Metástasis de la Neoplasia; Modelos de Riesgos Proporcionales; Receptores de Estrógenos/genética; Receptores de Progesterona/genética

Palabras clave

Breast cancer; Molecular subtypes; Pathological subtyping

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pronóstico / Neoplasias de la Mama / Biomarcadores de Tumor / Proteínas de Neoplasias Tipo de estudio: Guideline / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2018 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google